Objectives: To investigate the population pharmacokinetics of teicoplanin in patients treated by the subcutaneous (sc) and/or intravenous (iv) route.
Introduction
Teicoplanin is a glycopeptide antibiotic that is an alternative to vancomycin for the treatment of serious infections caused by Gram-positive bacteria, including MRSA. 1 Compared with vancomycin, teicoplanin has a longer terminal elimination half-life (ranging from 100 to 170 h) and so several days are necessary to achieve the steady-state. An appropriate loading dose is recommended to promptly achieve effective concentrations. Rapid achievement of effective concentrations is critical in the treatment of severe infections, especially in critically ill patients. [2] [3] [4] The traditional target for teicoplanin plasma concentration is the same as that for vancomycin, i.e. the trough concentration. For treating most MRSA infections, a trough concentration !15 mg/L is necessary to be clinically effective. 5, 6 More recently, the AUC 24 /MIC ratio has been reported as the pharmacokinetic (PK)/pharmacodynamic (PD) parameter linked with both bacteriological responses V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. J Antimicrob Chemother 2017; 72: 2804-2812 doi:10.1093/jac/dkx242 Advance Access publication 31 July 2017 and clinical effectiveness for the glycopeptide antibiotics. 7, 8 Matsumoto et al. 9 suggested an AUC 24 /MIC ratio !900 on day 3 as a target for optimal response to teicoplanin in patients with MRSA infections.
Concerning the characterization of teicoplanin-non-susceptible Staphylococcus aureus, Rose et al. 10 simulated and evaluated the development of reduced teicoplanin susceptibility in Staphylococcus over 72 h in an in vitro PD model. It appeared that high doses of 15 mg/kg with an AUC 24 /MIC ratio of 1800 (based on a free AUC 24 /MIC ratio of about 180 and assuming 90% protein binding) did not produce changes in MIC for any isolate tested.
Unlike vancomycin, teicoplanin is labelled for administration by both intravenous (iv) and intramuscular (im) routes of administration. Although still off-label, administration of teicoplanin by subcutaneous (sc) infusion may be convenient in some special populations, such as elderly hospitalized patients with poor venous access and outpatients with prolonged therapy. In France, the use of sc teicoplanin appears to be widespread in elderly patients and quite well tolerated. [11] [12] [13] [14] To our knowledge, Barbot et al. 15 have published the only study comparing the PK of sc and iv teicoplanin. They reported comparable exposure of teicoplanin administered by both routes in 12 critically ill patients. However, they did not use pharmacometric approaches to analyse these results and they did not suggest optimal dosage regimens of sc teicoplanin.
The aims of this study were: (i) to perform a population PK data analysis of teicoplanin administered by sc and iv routes; and (ii) to identify optimal loading dose regimens of teicoplanin in terms of efficacy and prevention of resistance.
Patients and methods

Ethics
This retrospective study was a joint population PK analysis of two datasets from patients treated with teicoplanin. The first dataset originated from the study of Barbot et al. 15 performed in 12 ICU patients at the University Hospital of Poitiers. This study was approved by the local Ethics Committee of the University Hospital of Poitiers (CCPPRB Poitou-Charentes, protocol number 01-02-05). The study design has been described in detail in the original publication. 15 The second dataset was collected in elderly patients hospitalized in geriatric units of the University Hospital of Lyon. Teicoplanin concentrations were measured under routine therapeutic drug monitoring conditions. Geriatric patients received teicoplanin by the iv or sc route or both for patients in whom a switch of route was necessary. This study was approved by the local Ethics Committee of the University Hospital of Lyon (Comité d'Ethique du CHU de Lyon, 23-06-2016). We performed joint modelling of all data.
Assay method
Available therapy data were teicoplanin dose, date, time of each administration, and infusion time. The date and time of each drug concentration were recorded precisely. For each patient, at least two blood samples were collected. Teicoplanin concentrations were measured by fluorescence polarization immunoassay with the Innofluor teicoplanin assay system on a TDX analyser (Abbott, France). The assay was linear from 5 to 100 mg/L.
PK modelling
Population PK analysis was performed using non-linear mixed-effects modelling within the Monolix software (version 4.4.0; http://lixoft.com/). Population PK parameters were estimated by maximum likelihood using the stochastic approximation expectation maximization (SAEM) algorithm combined with a Markov chain Monte Carlo procedure. 16 
Structural model
One-, two-and three-compartment models with two zero-order inputs to accommodate the two routes of administration (sc and iv) and no covariate were initially compared. Exponential random effects were assumed to describe between-subject variability. For example, for CL of subject i, CL i " CL pop % e gCL,i where CL pop is the population parameter estimate and g CL,i is the individual random effect . The values of g i were assumed to be normally distributed, with mean 0 and covariance x 2 parameterized as a diagonal matrix. Correlation between random effects was not estimated. Several error models were assessed for describing the residual variability (e). The most appropriate pharmacostatistical model was selected and evaluated on the basis of the following criteria: Bayesian information criterion (BIC), usual diagnostic plots and relative standard error (RSE) of estimated PK parameters. Regarding the sc route, we assumed a bioavailability of 100%, so parameters are expressed regardless of bioavailability.
Covariate analysis
From the basic model (without covariate), the influence of eight covariates on teicoplanin PK parameters was examined: age, gender, total body weight, ideal body weight, 17 lean body weight, 17 fat-free mass, 17 glomerular filtration rate (GFR) estimated by the Modification of Diet in Renal Disease (MDRD) equation and creatinine clearance estimated by the Cockcroft-Gault equation.
For continuous covariates, the parameter-covariate relationships were modelled as follows:
where b is the covariate effect to be estimated, COV i is the covariate value for subject i and COV median is the median value of the covariate in the study population. For binary covariates, the general equation was:
where COV i is 0 or 1. For all covariates, the unit of b is the logarithm of the unit of the associated parameter.
The covariate model was built using a stepwise procedure based on the BIC. 18 First, the one-covariate model with the smallest BIC was selected. Then, a two-covariate model was selected in a similar manner, and so on. The addition was stopped when no further decrease in the BIC was obtained. The final covariates model was obtained by a backward elimination procedure, removing covariates one by one, and computing the likelihood ratio test (LRT) for each reduced model. A covariate was retained in the model if the LRT was significant (P , 0.05, using a v 2 test with one degree of freedom) when it was removed from the full model. Moreover, a covariate was kept in the model if it was associated with a reduction in the betweensubject variability of the corresponding PK parameter and if the RSE of the covariate parameter was ,25%, and if the 95% confidence of the covariate coefficient (b) did not include zero (P , 0.05, Wald test).
Model internal validation
Evaluation of the model was based on goodness-of-fit plots. The model was first evaluated using plots of observations versus individual and Pharmacokinetics and dosing of sc and iv teicoplanin JAC population predictions. We then examined simulation-based plots [visual predictive check (VPC) plot and normalized prediction distribution error (NPDE) versus time]. As teicoplanin dosing regimens were not standardized, we performed a prediction-corrected VPC. 19 Monte Carlo simulation for evaluation of optimal dosage regimen Monte Carlo simulations were performed with SimulX (mlxR: R package version 3.0.0) using the final PK model with covariates to generate 1000 PK profiles of teicoplanin for each candidate regimen. Simulated teicoplanin trough concentrations and the AUC 24 were obtained for each condition. Two standard loading dose regimens and two high loading dose regimens were studied, as follows: 400, 600, 800 and 1000 mg twice daily for 48 h followed by the same dose administered once daily for 12 days with an infusion duration of 30 min. We simulated 1000 patients with a set of covariates resampled among the observed covariates (log-normally distributed) and a vector of random effects drawn from the estimated distribution. Thus, all simulations generated patients with variable renal function. The concentration-time profile of the 1000 virtual patients was simulated between 0 and 384 h. AUC values were divided by putative MIC values to derive AUC 24 /MIC ratios. The MIC values were selected from the EUCAST data and ranged from 0.25 to 4 mg/L. Currently, 2 mg/L is the teicoplanin susceptibility breakpoint for MRSA. 20 The trough concentrations and the AUC 24 /MIC were calculated over two 24 h periods: 48-72 h (day 3) and 336-360 h (day 15). For efficacy, the target trough was defined as C min !15 mg/L 21 and the target AUC 24 /MIC ratio was !900, as suggested by Matsumoto et al. 9 For preventing teicoplaninresistant S. aureus, the target AUC 24 /MIC ratio was !1800, as suggested by Rose et al.
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The target probability of target attainment (PTA) was calculated as the proportion of simulated patients achieving the target index value. A dosing regimen was defined as optimal if PTA was !90%.
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Results
Patients
Demographic and physiological characteristics of the study population are shown in Table 1 . The ranges of age, weight and renal function values were large. Almost one-quarter of patients received at least one sc infusion of teicoplanin.
Population PK analysis
A total of 862 concentrations were available for PK modelling. Teicoplanin PK concentrations were best described by a twocompartment linear model with an additional depot compartment for the sc route. A combined additive (with parameter a " 0.411 mg/L) and proportional (with coefficient b " 0.175) error model was used to describe the residual variability.
Estimated GFR based on the MDRD equation was found to influence teicoplanin elimination clearance and was the only covariate included in the final model. It was associated with a reduction in the variability of CL (xCL) from 35% to 28%. Surprisingly, body weight and other size metrics did not significantly influence teicoplanin PK in this population.
The final PK parameters are summarized in Table 2 . All were reliably estimated, with relatively small RSEs.
Model internal evaluation
The plots of observed concentrations versus population and individual model-based predictions are shown in Figure 1(a and b) . The final model described the data very well. Figure 1 (c and d) displays NPDE versus population predictions and time post-dose. No major trend was observed in those plots, which suggests no major prediction discrepancy.
The prediction-corrected VPC shown in Figure 1 (e) indicates that the model-based simulated quantities were in good agreement with teicoplanin measured concentration.
A stratified description by route of administration (sc and iv) of goodness-of-fit plots, NPDE and prediction-corrected VPC can be found in Figure S1 (available as Supplementary data at JAC Online).
Based on the above results and criteria, the model appeared to describe the data very well and to be internally validated. So, it was deemed to be adequate for further dosing simulations. Cazaubon et al.
Monte Carlo simulations for dosage regimen evaluation Figure 2 shows the simulated concentration-time profiles between 0 and 384 h calculated for the standard dosage regimen (400 mg every 12 h for 48 h followed by 400 mg every 24 h for 13 days) for both sc and iv routes. The sc route is associated with a much smoother profile, while the iv route produces a larger range of concentration values over a dosing interval. Importantly, for a given dose, the sc route was associated with lower C min and AUC initial values (day 3), but this difference appeared to vanish after 14 days, as a result of drug accumulation. Regarding the trough concentration target of efficacy (C min !15 mg/L), all sc and iv simulated dosing regimens achieved a PTA !90% except the 400 and 600 mg dosage regimens, as shown in Figure 3 . The PTA was especially poor (,50%) for the 400 mg dosage regimen. Importantly, the PTAs were remarkably similar between the sc and iv routes, suggesting that the sc route is not associated with a lower likelihood of response. Figure 4 (a and b) displays the PTA associated with the PK/PD target of efficacy, AUC 24 /MIC !900. After 2 days of therapy with twice daily administration, the 400 mg and 600 mg regimens failed to achieve a PTA !90% for MIC values .0.25-0.5 mg/L. The larger doses (800 and 1000 mg) were associated with larger PTA values. However, no dosage achieved 90% of PTA for the MRSA epidemiological cut-off (ECOFF) of MIC=2 mg/L. The iv route was associated with greater PTA than the sc route, especially for the lowest dosages and intermediate MIC values (0.25-1 mg/L). At day 15, the PTA of the 400 mg dose dramatically dropped to ,50% for both routes for an MIC of 1 mg/L. The other dosages provided higher PTA. The route of administration did not influence the PTA significantly. Again, no dosage regimen achieved optimal PTA values at the ECOFF. Figure 4(c and d) shows the attainment rate for the resistance suppression target (AUC 24 /MIC !1800). As this target is exactly 2-fold greater than the efficacy PK/PD target, the PTA values are all shifted one MIC to the left. As a consequence, this target was poorly achieved, especially after 2 days of therapy, except for the lowest MIC values ( 0.25 mg/L) and highest dosage regimens. Table 3 shows the mean and variability of simulated values of C min and AUC achieved with the various dosage regimens for both routes and stratified by renal function stages. As expected, the results show that drug exposure increased with increasing dose and decreasing renal function. High mean trough concentrations, .60 mg/L, were obtained on day 15 with the highest dosages of 800 and 1000 mg/L, even for normal and moderately impaired renal function.
Discussion
We studied the PK of teicoplanin administered by iv and sc infusion in 98 patients hospitalized in an ICU or geriatric units infected with MRSA/Staphylococcus epidermidis (88%) or Enterococcus spp. (12%), using a population approach. We found that teicoplanin concentrations were best described by a two-compartment model, in accordance with previously published data. [23] [24] [25] To our knowledge, this is the first population model describing the PK of teicoplanin administered by sc and iv routes.
The bioavailability by the sc route was not included in the final model because it did not improve the model fit. However, it was estimated at 97+14% (mean + SD) during model building. Based solely on rich data from the original study from Barbot et al., 15 mean bioavailability was estimated at 80%, with a standard error of 5%. This means that sc administration of teicoplanin may be considered as bioequivalent to iv administration, which is also the case for im administration. 26 The PK analysis yielded a similar range of parameter estimates to previous studies except for the CL. 23, 24 We believe that this discrepancy is due to the large proportion of elderly patients in our dataset compared with those studies.
The covariate analysis revealed that GFR as estimated by the MDRD equation was the only significant covariate influencing teicoplanin PK, which is consistent with the fact that teicoplanin is mainly eliminated unchanged by the kidney. 27 In previous studies, renal function estimated by creatinine clearance was also identified as a significant covariate influencing teicoplanin elimination. 23, 24, 28 High estimated GRF values were not capped in the final model, as this resulted in poorer fit (data not shown). No size metrics appeared to influence teicoplanin in our study population. This is consistent with previous population PK studies from Lortholary et al. 23 and Ogawa et al. 24 We then performed Monte Carlo simulations to evaluate the ability of several dosage regimens to achieve various target objectives, including a loading dose schedule. The dosing schedule and targets used in simulations were selected based on current standards. The EMA summary of product characteristics (SPC) of teicoplanin was revised in 2013. 21 The dose amount and duration of the loading dose regimen depends of the indication: 800 mg every 12 h for three to five administrations is now recommended for bone and joint infections (BJIs) and endocarditis, while 400 mg every 12 h for three administrations is recommended for other Pharmacokinetics and dosing of sc and iv teicoplanin Pharmacokinetics and dosing of sc and iv teicoplanin JAC infections. Ogawa et al. 24 suggested that an extended loading dose regimen could maximize the therapeutic effects of teicoplanin in patients with systemic MRSA infection. We simulated a loading dose regimen with five administrations every 12 h, as our objective was to identify a dosage regimen optimizing teicoplanin efficacy.
We used C min !15 mg/L as the target C min , as this is the suggested minimal value to be achieved in the SPC, although higher values are recommended in some infections (BJIs and endocarditis). While C min is a traditional index for glycopeptide therapeutic drug monitoring (TDM), it does not take into account bacterial susceptibility, which is known to influence the clinical outcome. 29 So, we also considered the AUC 24 /MIC ratio as a target based on recent evidence suggesting that this index is linked with both bacteriological efficacy and prevention of drug resistance. 9, 10 Our simulations provided several important results. First, a loading dose regimen with five administrations of either 400 or 600 mg is not sufficient to achieve the target C min !15 mg/L in most patients on day 3. A higher dose should be used (at least 800 mg) to achieve this target with a PTA !90%. Obviously, an even higher dose should be initially applied if a higher C min should be achieved, for example in the treatment of endocarditis. This result is in agreement with previous studies that suggested that higher doses should be used in the loading dosage regimen of teicoplanin. [30] [31] [32] This means that the loading dosage regimens recommended in the revised SPC are still inadequate regarding the ability to achieve the suggested C min targets, even the lowest one.
Second, we observed that the probability of achieving the target AUC 24 /MIC ratios suggested for efficacy (target ratio of 900) and prevention of drug resistance (target ratio of 1800) strongly depends on the MIC for the bacteria. The lowest dosages examined, 400 and 600 mg, are clearly suboptimal for achieving those targets on day 3 for MIC values !0.5 mg/L. The 800 and 1000 mg dosages provided higher PTAs, but these remain insufficient for early achievement of the targets for MIC values !1 mg/L. The PTAs were improved on day 15 and in patients with impaired renal function, for each dosage, but remained low for high MIC values.
This result raised questions about the rationale of these targets and the benefit/risk ratio of teicoplanin using such targets in clinical practice. For efficacy, while a ratio of 900 was identified by Matsumoto et al., 9 they show a large overlap of AUC values between the two groups (both success and failure occurred for values ranging from 300 to 1000 mg/L). For prevention of teicoplanin resistance, it is noteworthy that the results of Rose et al. 10 were dependent on the polymorphism of the accessory gene regulator (agr) in S. aureus (e.g. AUC 24 /MIC of 720 was sufficient to limit the increase in MIC for genotypes other than agr group I). To summarize, the AUC 24 /MIC target ratios identified for both efficacy and prevention of resistance seem questionable and remain to be confirmed clinically. However, if one would want to achieve such 18+7  1172+300  46+12  800  703+268  24+10  1562+400  61+16  1000  879+336  30+12  1953+500  77+20  iv  400  450+142  15+6  810+196  29+8  600  675+212  22+8  1215+294  44+12  800  900+283  29+11  1619+392  59+16  1000  1126+354  36+14  2024+490  73+20 Results are given as mean + SD.
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targets, our simulations clearly showed that teicoplanin doses much higher than currently recommended would be required (Table 3 ) to achieve sufficient AUC for both the loading and the maintenance regimens. As shown in Table 3 ). This raises concerns about safety, as unpublished studies from the teicoplanin manufacturer showed that patients with a teicoplanin C min .60 mg/L had a higher incidence of elevated serum creatinine levels compared with those with a teicoplanin C min of 20-40 mg/L [14/43 (33%) versus 4/36 (11%), P " 0.04]. 33 Third, our simulations clarify the implications of using the sc route instead of the iv route for teicoplanin PK/PD. Compared with the iv administration of the same dose, the sc administration resulted in similar C min and associated probability of achievement, but lower AUC and corresponding AUC 24 /MIC PTA values, especially during the loading phase. This suggests that sc therapy should not be used until patients have received an extended iv loading regimen, especially in patients with severe infection or who are infected with a bacteria with poor susceptibility (MIC !1 mg/L). In the maintenance phase, the sc route may be used as an alternative to the iv route, as it provides similar exposure and reduced C max (e.g. for 400 mg every 12 h at day 3, iv and sc median C max 50 and 12.5 mg/L, respectively; at day 15, 70 and 37.5 mg/L, respectively). As a reminder, C max values of sc and im routes of administration are similar and remain much less than the C max for the iv route. 26 As teicoplanin is a time-dependent antibiotic, C max should not be taken into account in terms of therapeutic efficacy.
The use of higher dosages of teicoplanin by the sc route may raise concerns about local tolerance, as daily doses .600 mg have been associated with more frequent reactions at the injection site. Splitting the dose and doing two administrations at two sc injection sites simultaneously may be a convenient way to optimize local tolerance. 13 Our study has several limitations. First, the analysis was based on data obtained in ICU and geriatric patients, so the results and conclusions may not hold true in other patient populations. Most geriatric patients had sparse PK data available, and overall data were limited in the absorptive phase. Tolerance of teicoplanin sc administration was not thoroughly evaluated in the geriatric patients. Regarding simulations, we used putative MIC values as individual MIC values were not available. The target AUC 24 /MIC ratios used in simulations were based on limited published data and are disputable, as discussed above. Clinical studies are necessary to assess the clinical utility and safety of teicoplanin doses higher than currently recommended. This is the first population model developed for iv and sc teicoplanin. Model-based simulations suggest that sc administration of teicoplanin results in trough concentrations similar to those obtained after iv administration, but lower AUC in the loading regimen. In the scenario of severe infection or poor susceptibility of MRSA (MIC !1 mg/L), an extended iv loading dose has to be preferred rather than sc administration. Loading doses of teicoplanin higher than currently recommended, at least 800 mg every 12 h, appear necessary for early achievement of C min !15 mg/L. Doses much higher than currently recommended would be necessary in patients infected with MRSA with MIC !1 mg/L to achieve AUC 24 /MIC target ratios identified in the literature. Such high doses may result in potentially toxic trough levels. TDM and Bayesian individualized dosage regimens remain essential tools to control drug levels and prevent overexposure in individuals. 2 
